ARMLUPEG
Launchpegfilgrastim-unne
BLASOLUTIONINJECTION
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ARMLUPEG (pegfilgrastim-unne) is colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARMLUPEG (pegfilgrastim-unne) is a biosimilar granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation and differentiation of hematopoietic cells by binding to specific cell surface receptors. It is indicated for patients receiving myelosuppressive chemotherapy to reduce the incidence of chemotherapy-induced neutropenia and its complications. The drug works by activating bone marrow stem cells to produce neutrophils, thereby maintaining adequate white blood cell counts during cancer treatment.
Launch
Early-stage launch product with moderate competitive pressure (30%) suggests active commercial team building and market entry strategies.
Mechanism of Action
colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARMLUPEG is at a critical launch phase with zero linked jobs currently posted, indicating either early internal staffing or imminent hiring as commercial operations scale. Working on this biosimilar entry product offers exposure to biosimilar market dynamics, payer negotiations, and competitive positioning in a high-volume therapeutic area.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.